Spark Investment Management LLC bought a new stake in shares of Aptinyx Inc (NASDAQ:APTX) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 60,400 shares of the company’s stock, valued at approximately $244,000.

Several other institutional investors have also added to or reduced their stakes in the company. Gabelli Funds LLC bought a new stake in Aptinyx in the first quarter valued at about $44,000. Geode Capital Management LLC increased its holdings in Aptinyx by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 107,464 shares of the company’s stock valued at $1,777,000 after purchasing an additional 17,914 shares during the last quarter. Millennium Management LLC bought a new stake in Aptinyx in the fourth quarter valued at about $266,000. Metropolitan Life Insurance Co. NY increased its holdings in Aptinyx by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the last quarter. Finally, Partner Fund Management L.P. increased its holdings in Aptinyx by 5.6% in the fourth quarter. Partner Fund Management L.P. now owns 1,852,132 shares of the company’s stock valued at $30,634,000 after purchasing an additional 97,453 shares during the last quarter. Institutional investors own 62.69% of the company’s stock.

NASDAQ:APTX traded up $0.07 on Friday, reaching $3.40. The company’s stock had a trading volume of 90 shares, compared to its average volume of 401,245. Aptinyx Inc has a 1-year low of $3.27 and a 1-year high of $32.25. The stock has a market cap of $111.76 million and a price-to-earnings ratio of -1.28.

Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.04). The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $1.00 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. As a group, equities analysts expect that Aptinyx Inc will post -2.25 earnings per share for the current year.

A number of research firms have issued reports on APTX. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. BMO Capital Markets reissued an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Finally, Zacks Investment Research cut Aptinyx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.95.

In other news, Director Henry O. Gosebruch acquired 100,000 shares of Aptinyx stock in a transaction dated Wednesday, May 8th. The stock was bought at an average cost of $3.86 per share, with a total value of $386,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.47% of the stock is owned by corporate insiders.

WARNING: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://theolympiareport.com/2019/05/24/spark-investment-management-llc-buys-shares-of-60400-aptinyx-inc-aptx.html.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Story: Total Return

Want to see what other hedge funds are holding APTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptinyx Inc (NASDAQ:APTX).

Institutional Ownership by Quarter for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.